|
Dec 20
|
Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema
|
|
Dec 19
|
13 Most Promising Healthcare Stocks According to Analysts
|
|
Dec 7
|
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
|
|
Dec 5
|
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
|
|
Nov 27
|
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
|
|
Nov 8
|
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
|
|
Nov 7
|
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
|
|
Sep 20
|
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
|
|
Aug 8
|
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
|
|
Aug 8
|
Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call
|
|
May 25
|
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
|
|
May 22
|
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
|